Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer therapeutics.
• HDACs play a critical role in gene expression regulation, influencing transcription activation and repression.
• Understanding the genome-wide impact of HDAC inhibition is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the genome-wide gene expression changes induced by Apicidin, a HDAC inhibitor.
• To identify a molecular signature associated with Apicidin treatment in a metastatic melanoma cell line.
• To elucidate the anti-tumor mechanisms of Apicidin, focusing on cell-cycle regulation.

Main Methods:

• Serial gene expression analyses were performed on MDA-MB-435 cells treated with Apicidin over 48 hours.
• Combined-transcriptomic analysis was employed to identify outlier genes.
• Gene expression data were validated by Western blot analysis.

Main Results:

• Apicidin treatment resulted in the identification of 631 outlier genes continuously up- or down-regulated over 48 hours.
• Cell-cycle suppression was identified as the most prominent biological process affected by Apicidin.
• Comprehensive negative regulation of the cell cycle was observed and validated.

Conclusions:

• The 631 outlier genes constitute a characteristic molecular signature for Apicidin.
• Transcriptional suppression of cell-cycle regulatory components is a potent anti-tumor mechanism of Apicidin.
• The identified genetic elements may offer novel therapeutic strategies for combating tumor metastasis.